• Cumberland Pharmaceuticals held a special shareholder meeting on June 24, 2026.
• Shareholders authorized the strategic transaction with Apotex tied to the April 22, 2026 asset purchase agreement.
• The resolution covered the sale of the company’s FDA-approved commercial products and related assets.
• The vote granted approval for the transaction terms, not confirmation that the sale has closed or been completed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cumberland Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001087294-26-000053), on June 25, 2026, and is solely responsible for the information contained therein.